Differences in circulating insulin levels following glargine administration.
OBJECTIVE
To evaluate two-site non competitive insulin immunoassays [BI-INSULIN assay (IRMA) and an electro-chemiluminescent immunoassay (ECLIA)] in routine practice.


METHODS
We studied 145 consecutive patients attending our Endocrine Department for general endocrine explorations and metabolic status investigations.


RESULTS
The ECLIA yielded higher results than IRMA in all but six patients treated by glargine.


CONCLUSIONS
Insulin levels measured by Elecsys in patients treated by glargine are directly related to glargine biotransformation into detectable metabolite (M1).
Ibrahim
Fidaa
F
Unit of Transfert in Molecular Oncology and Hormonology, Saint-Louis University Hospital, Assistance-Publique Hôpitaux de Paris, France.
Bagnard
Georges
G
Boudou
Philippe
P
D000328:Adult; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000378:metabolism; D015592:Immunoradiometric Assay / Q000379:methods*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008163:Luminescent Measurements / Q000379:methods*; D008297:Male; D008875:Middle Aged
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine